Efficacy of Iwnopriming Prior to Isolation of Tumor Infiltrating Lymphocytes for Use in Adoptive Immunotherapy

References

• Rosenberg S. A., Speiss P., Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumorinfiltrating lymphocytes. Science 1986; 233: 1318–1321
   PubMed Web of Science ®Google Scholar
• Rosenberg S. A. The development of new inmunotherapies for the treatment of cancer using interleukin-2. Ann. Surg. 1988; 208: 121–135
   PubMed Web of Science ®Google Scholar
• Yang J. C., Rosenberg S. A. Current approaches to the adoptive iamunotherapy of cancer. Cancer Metastasis, G. Prodi, L. A. Liotta, P. Lollini, et al. Plenum Press, New York 1988; 459
   Google Scholar
• Spiess P. J., Yang J. C., Rosenberg S. A. In vivo antitumor activity of tumor-infiltrating lymphocytes expanded in recombinant interleukin-2. J. Natl. Cancer Inst. 1987; 79: 1067–1075
   PubMed Web of Science ®Google Scholar
• Rosenberg S. A. Adoptive immunotherapy for cancer. Sci. Amer. May, 1990; 261: 62–69
   Google Scholar
• Heo D. S., Whiteside T. L., Kanbour A, Herbeman R. B. Lymphocytes infiltrating human ovarian tumor. I. Role of Leu-19 (NKH1)-positive recombinant IL-2 activated culture of lymphocytes infiltrating human ovarian tumors. J. Immunol. 1988; 140: 4042–4049
   PubMed Web of Science ®Google Scholar
• Davies M., Sabbadini E. Mechanisms of BCG action. I. Induction of non-specific helper cells during the potentiation of alloimmune cell-mediated cytotoxic responses. Cancer Inmunol. Immunother. 1982; 14: 46–53
   PubMed Web of Science ®Google Scholar
• Shapiro A., Ratliff T. L., Oakley D. M., Catalona W. J. Reduction of bladder tumor growth in mice treated with intravesical Bacillus Calmette-Guerin and natural killer cell activity. Cancer Res. 1983; 43: 1611–1615
   PubMed Web of Science ®Google Scholar
• Guinan P. D., Shaw M., Ray V. Histopathology of BCG and thiotepa treated tumors. Urol. Res. 1986; 14: 211–215
   PubMedGoogle Scholar
• Rubenstein M., Shaw M. W., Dubin A., McKiel C. F., Guinan P. D. Effect of BCG upon functional and phenotypic immune markers in rats bearing the Dunning R3327 MAT-LyLu prostatic adenocarcinoma. Immunopharmacol. Immunotoxicol. 1988; 10: 579–596
   PubMed Web of Science ®Google Scholar
• Guinan P. D., John T., Baumgartner G., Sundar B., Ablin R. J. Adjuvant immunotherapy (BCG) in stage D prostatic cancer. Am. J. Clin. Oncol. 1982; 5: 65–68
   PubMed Web of Science ®Google Scholar
• McKneally M. F., Maver C. M., Kausel H. W. Intrapleural BCG stimulation in lung cancer. Lancet 1977; 1: 593
   PubMedGoogle Scholar
• Hortobagyi G. N., Gutterman J. U., Blumenschein G. R., Tashima C. K., Burgess M. A., Einhorn L., Buzdarm A. U., Richman S. P., Hersh E. M. Combination chemoimmunotherapy of metastatic breast cancer with 5—fluorouracil, adriamycin, cyclophosphamide and BCG. Cancer 1979; 44: 1955–1962
   PubMed Web of Science ®Google Scholar
• Morton D. L., Eilber F. R., Malmgren R. A., Wood W. C. Immunological factors which influence response to immunotherapy in malignant melanoma. Surgery St. Louis 1970; 68: 158–164
   PubMed Web of Science ®Google Scholar
• Hanna M. G., Murray J. H., Pomato N., Bos E., Jessup J. M., McCabe R. P., Haspel M. V., Hoover H. C. Immunological characterization of colon tumor associated antigens. J. Cell. Biochem. 1988; 12E(supplement)125a
   Google Scholar
• Kaufmann S. H.E., Hahn H, Diamantstein T. Relative susceptibilities of T cell subsets involved in delayed-type hypersensitivity to sheep red blood cells to the in vitro action of 4—hydroperoxycyclophosphamide. J. Immunol. 1980; 125: 1104–1108
   PubMedGoogle Scholar
• Mitchell M. S. Combinations of chemotherapy and biomodulation in the treatment of cancer. J. Cell. Biochem. 1988; 12E(supplement)125A
   Google Scholar
• Rubenstein M., Shaw M. W., Bhatti R. A., Habibi H., Guinan P. D. The effect of low dose cyclophosphamide and immunologic exposure upon growth of established R3327–G subline rat prostate adenocarcinomas. The prostate 1985; 7: 151–159
   PubMed Web of Science ®Google Scholar
• Shaw M. W., Rubenstein M., Dubin A., McKiel C. F., Guinan P. D. The effect of cyclophosphamide on leukocytic subset distributions in rats carrying the Dunning R3327 MAT-LyLu prostatic adenocarcinoma. The Prostate 1987; 11: 117–125
   PubMedGoogle Scholar
• Isaacs J. T., Hukku B. Nonrandom involvement of chromosome 4 in the progression of rat prostatic cancer. The Prostate 1988; 13: 165–188
   PubMed Web of Science ®Google Scholar
• Boyum A. Separaton of leukocytes from blood and bone marrow. Scand. J. Clin. Invest. 1968; 21: 177–183
   PubMed Web of Science ®Google Scholar
• Hsu S.-M., Raine L., Fanger H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: A comparison between ABC and unlabeled antibody (PAP) procedures. J. Histochem. Cytochem. 1981; 29: 577–580
   PubMed Web of Science ®Google Scholar
• Williams A. F., Galfre G., Milstein C. Analysis of cell surfaces by xenogeneic myeloma-hybrid antibodies: differentiation antigens of rat lymphocytes. Cell 1977; 12: 663–673
   PubMed Web of Science ®Google Scholar
• Brideau R. J., Carter P. B., McMaster W. R., Mason D. W., Williams A. F. Two subsets of rat T lymphocytes defined with monoclonal antibodies. Eur. J. Immunol. 1980; 10: 609–615
   PubMed Web of Science ®Google Scholar